Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/18/2865336/0/en/Immutep-Appoints-Leading-Research-Institute-to-Conduct-First-in-Human-Phase-I-Study-of-IMP761.html
https://www.globenewswire.com/news-release/2024/04/17/2864453/0/en/Immutep-Receives-Positive-Feedback-from-the-Spanish-Medicines-Agency-for-Upcoming-TACTI-004-Registrational-Trial-in-Metastatic-Non-Small-Cell-Lung-Cancer.html
https://www.globenewswire.com//news-release/2024/03/05/2840402/0/en/Immutep-Announces-First-Clinical-Data-from-90mg-Dosing-of-Efti.html
https://www.globenewswire.com/news-release/2024/01/30/2819933/0/en/Immutep-Quarterly-Activities-Report-Q2-FY24.html
https://www.globenewswire.com//news-release/2023/12/21/2799956/0/en/Immutep-Receives-Constructive-Regulatory-Feedback-on-TACTI-004-Registrational-Trial-in-Metastatic-Non-Small-Cell-Lung-Cancer.html
https://www.globenewswire.com//news-release/2023/11/22/2784753/0/en/Immutep-Announces-Site-Expansion-for-INSIGHT-003-Phase-I-Trial.html
https://www.globenewswire.com//news-release/2023/11/09/2777267/0/en/Immutep-Completes-Enrollment-in-TACTI-003-Phase-IIb-Trial-of-Efti-and-KEYTRUDA-in-First-Line-Metastatic-or-Recurrent-Head-and-Neck-Squamous-Cell-Carcinoma.html
https://www.globenewswire.com//news-release/2023/11/03/2773320/0/en/Immutep-Announces-New-Biomarker-Data-from-TACTI-002-Phase-II-in-First-Line-Non-Small-Cell-Lung-Cancer.html
https://www.globenewswire.com//news-release/2023/11/02/2772258/0/en/Immutep-to-Participate-in-November-Investor-Events.html
https://www.globenewswire.com//news-release/2023/10/31/2770123/0/en/Immutep-Quarterly-Activities-Report-Q1-FY24.html